NCT07222280

Clinical Trial Protocol: Alzheimer's Dementia Underlying Encephalopathy

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Covenant Health, US · Academic / Other
• Sex: All
• Age: 60 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to determine if utilizing the Quest AD-Detect blood test, while patient's are hospitalized for a cognitive diagnosis (such as delirium or encephalopathy), will result in an earlier diagnosis of underlying Alzheimer's disease. * Will this blood test have the ability to distinguish between Alzheimer's disease and other causes of cognitive impairment in the inpatient setting? * Neurology Clinic will complete a 6-month post-hospitalization follow up with patients who have had the Quest AD-Detect Alzheimer's Disease blood test completed while they were inpatient to discuss the risk assessment portfolio

Conditions

• Alzheimer Dementia
• Alzheimer Disease
• Delirium Confusional State
• Encephalopathy
• Cognitive Abnormality

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Quest AD-Detect blood test	Blood will be collected and sent for testing using the Quest AD-Detect blood test

Timeline

• Start date: 2025-06-10
• Primary completion: 2026-03-31
• Completion: 2026-03-31
• First posted: 2025-10-29
• Last updated: 2025-10-29

Locations

6 sites across 1 country: United States

Regulatory

• FDA-regulated device study